Future Science Group
BMI_IO_SupplementaryTable1.docx (21.7 kB)

No association between body mass index and immunotoxicity or clinical outcomes for immune checkpoint inhibitors. Supplementary Table

Download (21.7 kB)
posted on 2022-06-13, 09:29 authored by Tara Baetza, Wilma Hopmana, Lilian Hanna, Gordon Taylor Moffat, Ryan Holsteada, Adi Kartoloa, Cynthia Yeunga


Supplementary Table 1. Development of immune-related adverse events (irAEs) and treatment response in patients with melanoma treated with immune checkpoint inhibitors at a single center, categorized by body mass index. Values are expressed as n (%), unless otherwise specified.